Keppra: The first and the only AED with Class I evidence in the treatment of myoclonic seizures in patients with JME

• Broad-spectrum efficacy as adjunctive therapy ¹



• Documented seizure freedom in patients with myoclonic seizures ¹
  


• Documented seizure freedom in patients with partial-onset seizures ^{13, 14}
  


• In adults: 9%(23/269) achieved seizure freedom with Keppra (levetiracetam)
  tablets vs 1% (3/367) for placebo ¹³
  


• In pediatric patients 4-16 years of age 7% (7/101) achieved seizure freedom with Keppra Oral solution vs 1% (1/97) for placebo ¹⁴


• No worsening of typical absence or PGTCS occurred ¹



• Rapid onset of action-seizure freedom documented at day 1 ¹



• No known clinically significant drug interactions ^7-10



• Long-term favourable tolerability with no Black Box warning ^11,12

Juvenile Myoclonic Epilepsy (JME): A common seizure syndrome affecting millions of patients

• JME affects approximately 7% of all people with epilepsy²



• True prevalence remains unclear since many cases are under diagnosed or misdiagnosed^3,4



• IGE seizure syndromes, such as JME, can be difficult to identify because features from one syndrome overlap with another^2,5
  
  
  • GTCS occurs in over 90% of patients with JME
  
  
  • Up to one third of patients with JME also experience absence seizures
  
  
  
  
• Establishing a correct diagnosis and prescribing effective therapy right from the start is critical to reduce patient morbidity⁶



• Usually requires lifelong treatment²

Seizure control with Lev. in JME

Significant seizure freedom achieved.¹

• Percent of refractory patients with myoclonic seizures achieving seizure freedom with Keppra as adjunctive therapy (during 12-week evaluation period)





• Percent of refractory patients achieving seizure freedom from all seizures*
  with Keppra as adjunctive therapy (during 12-week evaluation period)
  
  

1. Data on life. UCB S.A.
2. Nordli DR Jr. Idiopathic generalized epilepsies recognized by the International League against Epilepsy. Epilepsia. 2005;46(suppl):48-56.
3. Diagnosing juvenile myoclonic epilepsy (editorial). Lancet. 1992;340:759-760.
4. Zifkin B, Andermann E.,Andermann F. Mechanisms, genetics, and pathogenesis of juvenile myoclonic epilepsy. Curr Opin Neurol. 2005;18:147-153.
5. Gardiner M. Genetics of idiopathic generalized epilepsies. Epilepsia. 2005;46(suppl):15-20.
6. Renganathan R. Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J. 2003;79:78-80.
7. Perucca E. Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy res. 2003;53:47-56.
8. Regueneau-Majlessi i. levy RH. Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy res. 2001;47:55-63.
9. Ragueneau-Majlessi I, Levy RH, janik F. Levetiracetem does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia. Pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy res. 2001;46:93-99.
10. Keppra Summary of Product Characteristics (smpc), UCB S.A.
11. Ben-Menachem E, Edrich p, Van Vleymen B,et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy res. 2003;53:57-64.
12. Meencke H-J, Buyle s. Assessment of a dose-response relationship of levetiracetam. Eur j neurol. In press.
13. Glauser TA, Gauer, Lu Z, et al. Short-and long-term efficacy of levetiracetam adjunctive therapy in children with refractory partial epilepsy.
    Poster presented at: EFNS; September 14, 2005;Athens, Greece.